ArticleOTO open
Review of Ototoxic Drugs Using Health Insurance Data: A Data-Driven Management System.
Article in OTO open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: With more than 1.57 billion people affected by hearing loss worldwide, this study investigates the association between ototoxic drug use and hearing loss, utilizing South Korean national health data. The goal is to inform clinical prevention and management guidelines by identifying ototoxic drugs and assessing their risks. Study Design: This study is a retrospective observational study using the Health Insurance Review and Assessment Service (HIRA) to analyze the association between suspected ototoxic drug use and hearing loss. Setting: Data were obtained from the National Patient Samples (NPS) of HIRA in South Korea, covering 2009 to 2016. The study included all National Health Insurance (NHI) enrollees with at least one hospital visit. Methods: Patients diagnosed with suspected ototoxicity hearing loss (SOHL) were identified, and ototoxic drugs were reviewed using national data. Of 491 reviewed ingredients, 151 were suspected ototoxic. Logistic regression and Cox proportional hazards models assessed associations between drug prescriptions and SOHL, analyzed with SAS 9.4. Results: SOHL patients were older, with higher rates of underlying conditions and medication use compared to controls. The odds ratio (OR) for SOHL was significantly elevated in patients aged ≥65, increasing from 3.007 to 3.366. Proton pump inhibitors (PPIs) and antibiotics presented elevated risks, especially in older adults, with hazard ratios (HRs) for PPIs rising from 1.85 to 2.90. Notably, PPIs posed higher risks for patients <65. Conclusion: The study confirms that factors like age, gender, underlying diseases, and specific medications increase SOHL risk, emphasizing the need for cautious medication use tailored to age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.